基于网络药理学研究半夏泻心汤治疗溃疡性结肠炎的作用机制
Mechanism of Banxia Xiexin decoction on the treatment of ulcerative colitis by Network pharmacology
作者：刘胜伟,刘京东,王钰淳,廖原,何锦悦,沈正泽
Author：
收稿日期： 年卷（期）页码：2020,35(05):-572-578
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：半夏泻心汤;网络药理学;溃疡性结肠炎;靶标;蛋白相互作用;富集分析;作用机制
Key words：
基金项目：
中文摘要
目的应用网络药理学研究半夏泻心汤治疗溃疡性结肠炎的机制。方法通过TCMSP数据库收集半夏泻心汤全方7味中药的化合物及有效靶点,运用Cytoscape软件构建中药-活性成分-靶点网络;集合OMIM、TTD、GADCC、DRUGBANK数据库筛选的疾病靶点,与中药活性成分确定交集靶点的靶向关系;从String数据库构建靶点蛋白相互作用(PPI)网络;利用R语言clusterprofiler包进行基因功能GO分析和KEGG通路富集分析,并利用Cytoscape构建半夏泻心汤治疗溃疡性结肠炎的成分-靶标-通路网络图。结果筛选得到半夏泻心汤145个活性成分及作用于溃疡性结肠炎的靶标47个; PPI网络涉及47个节点,492条边,得到PTGS2、IL-6、TNF、IL-10、MMP9等10个Hub蛋白; GO分析表明:有效靶标参与了氧化应激、平滑肌细胞增殖和细胞因子活性等生物功能; KEGG通路分析发现:半夏泻心汤95.86%的活性成分与NF-κB、PTGS2、IL-6、TNF、IL-10等22个靶标及IL-17信号通路、TNF信号通路和炎症性肠病(IBD)显著相关。结论通过网络药理学预测了半夏泻心汤治疗溃疡性结肠炎的潜在机制,为其研究及开发提供了思路。
参考文献
[1] Iskandar HN,Dhere T,Farraye FA. Ulcerative colitis:Update on medical management[J]. Curr Gastroenterol Rep,2015,17(11):44.
[2] Ungaro R,Mehandru S,Allen PB,et al. Ulcerative colitis[J].Lancet,2017,389:1756-1770.
[3] Adams SM,Bornemann PH. Ulcerative colitis[J]. Am Fam Physician,2013,87(10):699-705.
[4] Silva BC,Lyra AC,Rocha R. Epidemiology,demographic characteristics and prognostic predictors of ulcerative colitis[J]. World J Gastroenterol,2014,20(28):9458-9467.
[5]张胜，陈立江，车轶，等．半夏泻心汤药理研究最新进展[J]．中国中药杂志，2001,26(7):437-439.
[6]裴强伟，孙志翠，宋小莉，等．半夏泻心汤及其加减方治疗溃疡性结肠炎疗效和安全性的系统评价[J]．中国实验方剂学杂志，2012,14:290-294.
[7]吴勇惠，方明亮，张武林．常规西药三联疗法联合半夏泻心汤治疗胃溃疡的临床效果观察[J]．中国中西医结合消化杂志，2014,2:102-103.
[8]张吉仲，李利民，黄利，等．半夏泻心汤及其拆方对脾虚大鼠下丘脑中多巴胺、去甲肾上腺素和5-羟色胺的影响[J]．华西药学杂志，2014,29(3):286-288.
[9]刘珺，黄咏梅，王晖．网络药理学的研究进展[J]．华西药学杂志，2014,29(6):723-725.
[10]吴纯伟，路丽，梁生旺，等．药物靶标预测技术在中药网络药理学中的应用[J]．中国中药杂志，2016,41(3):377-382.
[11] Li S,Fan TP,Jia W,et al. Network pharmacology in traditional chinese medicine[J]. Evid Based Complement Alternat Med,2014,2014:138460.
[12]汪悦，查安生．中医药对溃疡性结肠炎作用机制的干预研究[J]．中华中医药学刊，2015,2:394-396.
[13] Ru J,Li P,Wang J,et al. TCMSP:A database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminformatics,2014,6(1):13.
[14] Yu G,Wang LG,Han Y,et al. ClusterProfiler:An R package for comparing biological themes among gene clusters[J].Omics:A J Integr Biology,2012,16(5):284-287.
[15] Goos J,Hiemstra AC,CoupéVMH,et al. Epidermal growth factor receptor(EGFR)and prostaglandin-endoperoxide synthase 2(PTGS2)are prognostic biomarkers for patients with resected colorectal cancer liver metastases[J]. Br J Cancer,2014,111(4):749-755.
[16] Yi X,Lin J,Luo H,et al. Genetic variants of PTGS2,TXA2R and TXAS1 are associated with carotid plaque vulnerability,platelet activation and TXA2 levels in ischemic stroke patients[J]. Plos One,2017,12(7):e0180704.
[17] Koo JB,Nam MO,Jung Y,et al. Anti-fibrogenic effect of PPAR-γagonists in human intestinal myofibroblasts[J].BMC gastroenterol,2017,17(1):73.
[18] Wei J,Ghosh AK,Sargent JL,et al. PPARγdownregulation by TGF in fibroblast and impaired expression and function in systemic sclerosis:A novel mechanism for progressive fibrogenesis[J]. Plos One,2010,5(11):e13778.
[19] Xiong ZY,Huang HC,Li J,et al. Anti-inflammatory effect of PPARγin cultured human mesangial cells[J]. Renal Failure,2004,26(5):97-505.
[20] Garg P,Vijay-Kumar M,Wang L,et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis[J]. Am J Physiol Gastrointest Liver Physiol,2009,296(2):G175-G184.
[21] Medina C,Santana A,Paz M C,et al. Matrix metalloproteinase-9modulates intestinal injury in rats with transmural colitis[J].J Leukocyte Biology,2006,79(5):954-962.
[22] Ravi A,Garg P,Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease:Boon or a bane?[J]. Inflamm Bowel Dis,2007,13(1):97-107.
[23]张善金，李弼民．NF-κB信号通路与炎症性肠病[J]．世界华人消化杂志，2011,19(5):505-509.
[24] Bantel H,Berg C,Vieth M,et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis[J]. Am J Gastroenterol,2000,95(12):3452-3457.
[25]施沛青，朱书，钱友存．IL-17的信号传导及功能研究[J]．中国细胞生物学学报，2011,33(4):345-357.
[26] Fujino S,Andoh A,Bamba S,et al. Increased expression of interleukin 17 in inflammatory bowel disease[J]. Gut,2003,52(1):65-70.
[27] Hundorfean G,Neurath MF,Mudter J. Functional relevance of T helper 17(Th17)cells and the IL-17 cytokine family in inflammatory bowel disease[J]. Inflamm Bowel Dis,2011,18(1):180-186.
[28] Karaboga,Demirtas S,Karaca T. Investigation of the relationship between the Th17/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats[J]. Iran J Basic Med Sci,2017,20(8):870-879.
[29] Lin H,Zhang W,Jiang X,et al. Total glucosides of paeony ameliorates TNBS-induced colitis by modulating differentiation of Th17/Treg cells and the secretion of cytokines[J].Mol Med Rep,2017,16(6):8265-8276.
[30]时丹丹，王乾，谢培，等．半夏泻心汤及其拆方对TNBS致溃疡性结肠炎模型大鼠结肠组织细胞因子的影响[J]．陕西中医药大学学报，2018,5:114-118.
[31] Fitzpatrick LR. Novel pharmacological approaches for inflammatory bowel disease:Targeting key intracellular pathways and the IL-23/IL-17 axis[J]. Int J Inflam,2012,2012:ID389404.
下一条：滴丸剂的剂型研究及临床应用进展
【关闭】
